A Phase Ib Study of Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Latest Information Update: 24 Nov 2023
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms PALACE; PALACE-1
Most Recent Events
- 20 Nov 2023 Status changed from active, no longer recruiting to completed.
- 26 Dec 2020 Results published in the European Journal of Cancer
- 31 May 2020 Planned End Date changed from 17 Mar 2020 to 17 Jun 2020.